Impact of renal aging on drug therapy

Postgraduate Medicine

Volumn 127, Issue 6, 2015, Pages 623-629

  Musso, Carlos G ^a   Belloso, Waldo H ^a   Scibona, Paula ^a   Bellizzi, Vincenzo ^b   Macías Núñez, Juan F ^c  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Gastroenterology Unit   (Italy)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Aging; Dosing; Kidney; Pharmacology; Renal function

Indexed keywords

ALISKIREN; AMILORIDE; AMINOGLYCOSIDE; AMPHOTERICIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; CISPLATIN; COTRIMOXAZOLE; DEXTROPROPOXYPHENE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENOXAPARINE; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; INDOMETACIN; LAXATIVE; LOOP DIURETIC AGENT; METHOTREXATE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PETHIDINE; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; AGING; ARTICLE; BLEEDING; BODY COMPOSITION; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; DIURESIS; DYSAUTONOMIA; END STAGE RENAL DISEASE; FREE WATER CLEARANCE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOVOLEMIA; PARATHYROID HORMONE BLOOD LEVEL; PHARMACOLOGICAL PARAMETERS; POLYPHARMACY; RENAL AGING; AGED; DRUG MONITORING; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; AGING; DRUG MONITORING; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; POLYPHARMACY;

EID: 84944147355     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2015.1063957     Document Type: Article

References (61)

1. Waltman K WS. Preventing adverse drug reactions. Philadelphia: Hanley & Belfus; 2000.
2. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5:345–51.
3. Weiss BD, Lee JK. Aging: Is your patient taking too many pills? J Fam Pract 2012;61:652–61.
4. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003;78:1564–77.
5. Willlams CM. Using medications appropriately in older adults. Am Fam Physician 2002;66:1917–24.
6. Musso CG. Geriatric nephrology and the “nephrogeriatric giants”. Int Urol Nephrol 2002;34:255–6.
7. Musso CG. Acute renal failure in the elderly: pearls for its assessment and treatment. Electron J Biomed 2005;1:1–93.
8. Renkke H, Denker B. Renal pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2007.
9. Onuigbo MA, Onuigbo NT. The syndrome of rapid onset endstage renal disease (SOROESRD) – A new mayo clinic dialysis services experience, January 2010-February 2011. In Di Iorio B, Heidland A, Onuigbo M, Ronco C, Editors. Hemodialysis: When, How, Why. New York, NY: NOVA Publishers; 2012; p 443–85.
10. Onuigbo M, Onuigbo N, Musso CG. Syndrome of rapid-onset endstage renal disease in incident Mayo Clinic chronic hemodialysis patients. Indian J Nephrol 2014;24:75–81.
11. Musso CG, Jauregui J. Renin-angiotensin-aldosterone system and the aging kidney. Endocrinol Metab 2014;9:1–4.
12. Musso CG, Oreopoulos D. Renal changes in the elderly. In Katlic M, Editor. Cardiothoracic surgery in the elderly. Evidencebased practice. New York: Springer; 2011.
13. Musso CG, Macias Nunez JF, Oreopoulos DG. Physiological similarities and differences between renal aging and chronic renal disease. J Nephrol 2007;20:586–7.
14. Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol 2011;119:(Suppl 1):1–5.
15. Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res 2004;24:49–54.
16. Torner A, Odar-Cederlof I, Kallner A, Akner G. Renal function in community-dwelling frail elderly. Comparison between measured and predicted glomerular filtration rate in the elderly and proposal for a new cystatin C-based prediction equation. Aging Clin Exp Res 2008;20:216–25.
17. Wei L, Ye X, Pei X, Wu J, Zhao W. Reference intervals for serum cystatin C and factors influencing cystatin C levels other than renal function in the elderly. PLoS One 2014;9:e86066.
18. Keller F. Kidney function and age. Nephrol Dial Transplant 1987;2:382.
19. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007;72:632–7.
20. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010;5:314–27.
21. Musso CG, Oreopoulos D. Geriatric nephrology. In Pathy J, Sinclair A, Morley J, Editors. Principles and practice of geriatric medicine. West Sussex: Wiley; 2012.
22. Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012;157:471–8.
23. Alshaer IM, Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, et al. External validation of the Berlin equations for estimation of GFR in the elderly. Am J Kidney Dis 2014;63:862–5.
24. Denneboom W, Dautzenberg MG, Grol R, De Smet PA. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006;56:504–10.
25. Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald DL. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis or hepatic impairment. Epilepsy Res 2014;108:891–901.
26. Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, Johannessen SI. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit 2012;34:440–5.
27. Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther 2012;34:201–13.
28. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 2015;3:1–10.
29. Scibona P, Angriman F, Vazquez C, Ferreyro BL, Perelsztein AG, Simonovich VA, Jauregui JR, et al. Individualisation of drug therapy in older people. Rev Clin Gerontol 2014;24:145–57.
30. Musso CG, Michelángelo H, Vilas M, Reynaldi J, Martinez B, Algranati L, Macías Núñez JF. Creatinine reabsorption by the aged kidney. Int Urol Nephrol 2009;41:727–31.
31. Musso CG, Ghezzi L, Ferraris J. Renal physiology in newborns and old people: similar characteristics but different mechanisms. Int Urol Nephrol 2004;36:273–6.
32. Musso CG, Macías-Núñez JF. Dysfunction of the thick loop of Henle and senescence: from molecular biology to clinical geriatrics. Int Urol Nephrol 2011;43:249–52.
33. Musso CG, Miguel Rd, Algranati L, Farias Edos R. Renal potassium excretion: comparison between chronic renal disease patients and old people. Int Urol Nephrol 2005;37:167–70.
34. Musso C, Liakopoulos De Miguel R, Imperiali N, Algranati L. Transtubular potassium concentration gradient: comparison between healthy old people and chronic renal failure patients. Int Urol Nephrol 2006;38:387–90.
35. Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook. Philadelphia: Lexi-Comp; 2004. p 646–8.
36. Musso CG, Juarez R, Vilas M, Navarro M, Rivera H, Jauregui R. Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III- chronic kidney disease and healthy oldest old. Int Urol Nephrol 2012;44:1559–62.
37. Musso CG, Alvarez Gregory J, Macías Núñez JF. Renal handling of uric acid, magnesium, phosphorus, calcium, and acid base in the elderly. In Núñez M, Cameron S, Oreopoulos D, Editors. Renal ageing: health and disease. New York: Springer; 2008. p 155–71.
38. Musso CG. Magnesium metabolism in health and disease. Int Urol Nephrol 2009;41:357–62.
39. Musso CG, Reynaldi J, Vilas M, De Miguel R, Imperiali N, Algranati L. Fractional excretion of K, Na and Cl following furosemide infusion in healthy, young and very old people. Int Urol Nephrol 2010;42:273–7.
40. Musso CG, Macías Núñez JF. Renal handling of water and electrolytes in the old and old-old healthy aged. In Núñez M, Cameron S, Oreopoulos D, Editors. Renal ageing: health and disease. New York: Springer; 2008. p 141–54.
41. Fulop T Jr, Worum I, Csongor J, Foris G, Leovey A. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 1985;31:6–14.
42. Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 2005;113:1243–9.
43. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163–84.
44. Perucca E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol 2007;81:183–99.
45. Noreddin AM, Haynes V. Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. Drugs Aging 2007;24:275–92.
46. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008;47:297–321.
47. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007;370:185–91.
48. Yoo SH, Kwon SU, Jo MW, Kang DW, Kim JS. Age and weight adjusted warfarin initiation nomogram for ischaemic stroke patients. Eur J Neurol 2012;19:1547–53.
49. Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, Allon M, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56:823–31.
50. Frishman WH, Aronow WS. Pharmacology of antiarrhythmic drugs in elderly patients. Clin Geriatr Med 2012;28:575–615.
51. Wang L. Changes in pharmacokinetics in the elderly and therapeutic drug monitoring of antiarrhythmic drugs. Life Sci J 2007;4:1–7.
52. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet 1976;1:126–34.
53. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521–90.
54. Ruiz JG, Array S, Lowenthal DT. Therapeutic Drug Monitoring in the Elderly. Am J Ther 1996;3:839–60.
55. Ghiculescu R. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescriber 2008;31:42–4.
56. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67–76.
57. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). Clin Pharmacokinet 1991;21:262–73.
58. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000;101:354–9.
59. Bonetti A, Franceschi T, Apostoli P, Cetto GL, Recaldin E, Molino A, et al. Cisplatin pharmacokinetics in elderly patients. Ther Drug Monit 1994;16:477–82.
60. Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1986;8:249–55.
61. Waade RB, Molden E, Refsum H, Hermann M. Serum Concentrations of Antidepressants in the elderly. Ther Drug Monit 2012;34:25–30.